Flavia V. Castelino, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Scleroderma, Systemic | 21 | 2023 | 344 | 5.760 |
Why?
|
Lung Diseases, Interstitial | 10 | 2023 | 909 | 2.100 |
Why?
|
Lysophospholipids | 3 | 2016 | 338 | 0.930 |
Why?
|
Scleroderma, Diffuse | 4 | 2023 | 18 | 0.760 |
Why?
|
Hypertension, Pulmonary | 2 | 2023 | 1564 | 0.670 |
Why?
|
Phosphoric Diester Hydrolases | 2 | 2016 | 198 | 0.640 |
Why?
|
Skin | 6 | 2023 | 4464 | 0.580 |
Why?
|
Benzoates | 2 | 2016 | 211 | 0.520 |
Why?
|
Receptors, Lysophosphatidic Acid | 2 | 2012 | 77 | 0.480 |
Why?
|
Coronary Aneurysm | 1 | 2016 | 231 | 0.450 |
Why?
|
Pulmonary Fibrosis | 2 | 2016 | 506 | 0.410 |
Why?
|
Scleroderma, Localized | 2 | 2023 | 87 | 0.400 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2016 | 537 | 0.380 |
Why?
|
Connective Tissue Diseases | 2 | 2013 | 285 | 0.380 |
Why?
|
Fibroblasts | 3 | 2016 | 4087 | 0.380 |
Why?
|
Acro-Osteolysis | 2 | 2020 | 3 | 0.370 |
Why?
|
Eicosanoids | 1 | 2012 | 278 | 0.370 |
Why?
|
Autoimmunity | 1 | 2018 | 1358 | 0.360 |
Why?
|
Hypertension, Malignant | 1 | 2019 | 17 | 0.340 |
Why?
|
Chest Pain | 1 | 2016 | 1090 | 0.330 |
Why?
|
Disease Management | 1 | 2018 | 2500 | 0.300 |
Why?
|
Paresthesia | 1 | 2008 | 162 | 0.290 |
Why?
|
Interleukin-6 | 1 | 2016 | 3208 | 0.270 |
Why?
|
Bleomycin | 3 | 2016 | 495 | 0.250 |
Why?
|
Gastrointestinal Diseases | 2 | 2023 | 1185 | 0.240 |
Why?
|
Vital Capacity | 3 | 2021 | 962 | 0.230 |
Why?
|
Inflammation Mediators | 1 | 2012 | 1878 | 0.220 |
Why?
|
Fibrosis | 3 | 2016 | 2038 | 0.210 |
Why?
|
Registries | 6 | 2023 | 8175 | 0.200 |
Why?
|
Calcinosis | 2 | 2022 | 1467 | 0.200 |
Why?
|
Tobacco Use Cessation | 1 | 2023 | 93 | 0.200 |
Why?
|
Lung | 4 | 2023 | 9985 | 0.180 |
Why?
|
Cytokines | 2 | 2016 | 7338 | 0.180 |
Why?
|
Rheumatology | 2 | 2018 | 611 | 0.180 |
Why?
|
Headache | 1 | 2008 | 1248 | 0.180 |
Why?
|
Idiopathic Pulmonary Fibrosis | 2 | 2013 | 500 | 0.140 |
Why?
|
Interinstitutional Relations | 1 | 2018 | 236 | 0.140 |
Why?
|
Acute Kidney Injury | 1 | 2019 | 1926 | 0.140 |
Why?
|
Respiratory Function Tests | 2 | 2019 | 1680 | 0.130 |
Why?
|
Severity of Illness Index | 6 | 2023 | 15785 | 0.130 |
Why?
|
Gastroesophageal Reflux | 1 | 2023 | 816 | 0.130 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2016 | 213 | 0.130 |
Why?
|
Mycophenolic Acid | 3 | 2023 | 343 | 0.130 |
Why?
|
Rheumatic Diseases | 1 | 2022 | 639 | 0.120 |
Why?
|
Kidney | 2 | 2019 | 7016 | 0.120 |
Why?
|
Adaptive Immunity | 1 | 2019 | 726 | 0.120 |
Why?
|
Humans | 31 | 2023 | 758406 | 0.110 |
Why?
|
Immune System Diseases | 1 | 2016 | 258 | 0.110 |
Why?
|
Research Personnel | 1 | 2018 | 582 | 0.110 |
Why?
|
Biomarkers, Pharmacological | 1 | 2013 | 162 | 0.100 |
Why?
|
Mentors | 1 | 2018 | 660 | 0.100 |
Why?
|
Needs Assessment | 1 | 2018 | 1141 | 0.100 |
Why?
|
Immunosuppressive Agents | 2 | 2023 | 4158 | 0.100 |
Why?
|
Signal Transduction | 1 | 2014 | 23342 | 0.100 |
Why?
|
Hand | 3 | 2022 | 903 | 0.090 |
Why?
|
Lung Injury | 1 | 2016 | 424 | 0.090 |
Why?
|
Biomedical Research | 2 | 2018 | 3418 | 0.090 |
Why?
|
Longitudinal Studies | 3 | 2021 | 14490 | 0.090 |
Why?
|
Immunohistochemistry | 2 | 2016 | 11070 | 0.090 |
Why?
|
Disease Models, Animal | 3 | 2016 | 18119 | 0.090 |
Why?
|
Consensus | 2 | 2023 | 3099 | 0.080 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 3801 | 0.080 |
Why?
|
Labetalol | 1 | 2008 | 29 | 0.080 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2016 | 1765 | 0.080 |
Why?
|
Sural Nerve | 1 | 2008 | 105 | 0.080 |
Why?
|
Amlodipine | 1 | 2008 | 84 | 0.080 |
Why?
|
Anemia, Hemolytic | 1 | 2019 | 163 | 0.080 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 3432 | 0.070 |
Why?
|
Immunity, Innate | 1 | 2019 | 3047 | 0.070 |
Why?
|
Guanine | 1 | 2008 | 278 | 0.070 |
Why?
|
Adult | 10 | 2022 | 219935 | 0.070 |
Why?
|
Proteinuria | 1 | 2019 | 594 | 0.070 |
Why?
|
Animals | 6 | 2016 | 167768 | 0.060 |
Why?
|
Drug Discovery | 1 | 2013 | 1044 | 0.060 |
Why?
|
Education, Medical, Graduate | 1 | 2018 | 2359 | 0.060 |
Why?
|
Delphi Technique | 1 | 2019 | 829 | 0.060 |
Why?
|
Phenotype | 1 | 2023 | 16534 | 0.060 |
Why?
|
Morbidity | 1 | 2010 | 1754 | 0.060 |
Why?
|
Autoantibodies | 1 | 2013 | 2118 | 0.060 |
Why?
|
Coronary Angiography | 1 | 2016 | 4451 | 0.060 |
Why?
|
Echocardiography | 1 | 2017 | 4962 | 0.060 |
Why?
|
Vasculitis | 1 | 2008 | 522 | 0.060 |
Why?
|
Immunoglobulin G | 1 | 2016 | 4540 | 0.060 |
Why?
|
Female | 11 | 2022 | 390323 | 0.060 |
Why?
|
Substance Abuse, Intravenous | 1 | 2008 | 529 | 0.060 |
Why?
|
Prednisone | 1 | 2008 | 1565 | 0.060 |
Why?
|
Hepatitis B | 1 | 2008 | 701 | 0.050 |
Why?
|
Electrocardiography | 1 | 2016 | 6363 | 0.050 |
Why?
|
Biopsy | 2 | 2019 | 6768 | 0.050 |
Why?
|
Middle Aged | 8 | 2022 | 219568 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10146 | 0.050 |
Why?
|
Sequence Analysis, RNA | 2 | 2019 | 2001 | 0.050 |
Why?
|
Chemokine CCL8 | 1 | 2021 | 17 | 0.050 |
Why?
|
Disease Progression | 1 | 2018 | 13468 | 0.050 |
Why?
|
Chemokine CCL19 | 1 | 2021 | 35 | 0.050 |
Why?
|
Mass Screening | 1 | 2017 | 5427 | 0.050 |
Why?
|
Chemokine CXCL9 | 1 | 2021 | 135 | 0.050 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2008 | 1373 | 0.050 |
Why?
|
Male | 10 | 2022 | 358747 | 0.050 |
Why?
|
beta 2-Microglobulin | 1 | 2021 | 328 | 0.040 |
Why?
|
Self Report | 2 | 2023 | 3714 | 0.040 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2022 | 288 | 0.040 |
Why?
|
Chemokine CXCL10 | 1 | 2021 | 316 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 346 | 0.040 |
Why?
|
Raynaud Disease | 1 | 2019 | 79 | 0.040 |
Why?
|
Patient Care Team | 1 | 2010 | 2504 | 0.040 |
Why?
|
Mice | 3 | 2016 | 81101 | 0.040 |
Why?
|
United States | 3 | 2021 | 72136 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2016 | 22029 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2008 | 6293 | 0.040 |
Why?
|
Prognosis | 2 | 2021 | 29557 | 0.040 |
Why?
|
Physicians | 1 | 2015 | 4580 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15225 | 0.040 |
Why?
|
Uncertainty | 1 | 2022 | 751 | 0.030 |
Why?
|
Submandibular Gland | 1 | 2016 | 87 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2011 | 14354 | 0.030 |
Why?
|
Retroperitoneal Space | 1 | 2016 | 171 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2021 | 2218 | 0.030 |
Why?
|
Nasal Septum | 1 | 2016 | 130 | 0.030 |
Why?
|
Methotrexate | 1 | 2021 | 1719 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2013 | 12604 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2017 | 20500 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2016 | 778 | 0.030 |
Why?
|
Blood Pressure | 1 | 2019 | 8451 | 0.030 |
Why?
|
Treatment Outcome | 3 | 2023 | 64378 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2008 | 12951 | 0.030 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2016 | 675 | 0.030 |
Why?
|
Program Development | 1 | 2018 | 1298 | 0.020 |
Why?
|
Ischemia | 1 | 2020 | 1863 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2018 | 1501 | 0.020 |
Why?
|
Aged | 4 | 2021 | 168218 | 0.020 |
Why?
|
Regression Analysis | 1 | 2019 | 6354 | 0.020 |
Why?
|
Hypertension | 1 | 2019 | 8499 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2013 | 799 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 3234 | 0.020 |
Why?
|
Qualitative Research | 1 | 2018 | 2976 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3615 | 0.020 |
Why?
|
International Cooperation | 1 | 2013 | 1430 | 0.020 |
Why?
|
Gene Expression | 1 | 2019 | 7583 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12096 | 0.020 |
Why?
|
Prospective Studies | 2 | 2021 | 54137 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2019 | 12262 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2010 | 58683 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2751 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2016 | 3485 | 0.010 |
Why?
|
Curriculum | 1 | 2018 | 3717 | 0.010 |
Why?
|
Databases, Factual | 1 | 2019 | 7980 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9404 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2022 | 20055 | 0.010 |
Why?
|
Risk Factors | 1 | 2010 | 73809 | 0.010 |
Why?
|
Depression | 1 | 2022 | 8057 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 13285 | 0.010 |
Why?
|
Societies, Medical | 1 | 2013 | 3891 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41256 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 11892 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 22003 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 58808 | 0.010 |
Why?
|
Adolescent | 1 | 2019 | 87892 | 0.010 |
Why?
|